Characteristics and clinical features of essential thrombocythemia patients with and without pulmonary hypertension.
With PH (N=19) | Without PH (N=102) | ||
---|---|---|---|
Age (yr), median (range) | 65 (22–79) | 66 (29–88) | 0.536 |
Gender, male:female | 6:13 | 56:46 | 0.062 |
IPSET, N (%) | 0.071 | ||
Low | 1 (5.3) | 26 (25.5) | |
Intermediate | 9 (47.4) | 27 (26.5) | |
High | 9 (47.4) | 49 (48.0) | |
Laboratory findings, mean±SD | |||
WBC (×109/L) | 11.4±4.6 | 12.9±6.2 | 0.398 |
Monocyte (×109/L) | 0.6±0.2 | 0.8±0.6 | 0.429 |
Hemoglobin (g/dL) | 13.1±2.6 | 13.9±2.1 | 0.176 |
Platelet (×109/L) | 1,152.2±572.0 | 968.8±377.6 | 0.107 |
LDH (×UNL) | 1.4±0.4 | 1.2±0.5 | 0.094 |
Driver gene mutations, N (%) | 0.080 | ||
9/14 (64.3) | 67/84 (79.8) | ||
4/14 (28.6) | 6/84 (7.1) | ||
Comorbidity, N (%) | |||
Diabetes mellitus | 3 (15.8) | 14 (13.7) | 0.812 |
Hypertension | 12 (63.2) | 41 (40.2) | 0.064 |
Chronic kidney disease | 4 (21.1) | 20 (19.6) | 0.885 |
Smoking | 2 (10.5) | 26 (25.5) | 0.363 |
Thrombotic eventsa) | 8 (42.1) | 37 (36.3) | 0.797 |
Follow-up duration (yr), median (range) | 7.1 (1.1–18.1) | 3.7 (0.1–21.4) | 0.032 |
a)Overall thrombotic events (before, at the time of, and after diagnosis).
Abbreviations: CALR, calreticulin; IPSET, International Prognostic Score for Essential Thrombocythemia; LDH, lactate dehydrogenase; PH, pulmonary hypertension; UNL, upper normal limit.